{"title":"Diagnostic value of three urine miRNAs composite score in BK virus nephropathy.","authors":"Zhoufan Zhang, Changling Cao, Cuello Garcia Haider, Yinfeng Wang, Yiying Zhu, Ouzaouit Abdelhak, Haitao Liu, Chenzhen Yu, Sheng Chang, Weijie Zhang, Tingya Jiang, Yang Zhou","doi":"10.1016/j.cca.2025.120162","DOIUrl":null,"url":null,"abstract":"<p><p>Noninvasive detection of BK virus, for early detection of BK polyomavirus-associated nephropathy post-renal transplantation, is currently an active subject of investigation. In this study, we developed and validated a novel risk score diagnostic assay (PymiR Score) based on measurements of three urine miRNAs, including BKV-related miRNA (bkv-miR-B1-5p), polyomavirus-related miRNA (bkv-miR-B1-3p) and renal tubular injury-related miRNA (miR-21-5p), by quantitative polymerase chain reaction. The limit of detection of the three miRNAs was 2 × 10<sup>3</sup> copies/mL, while the intra- and inter-assay coefficients of variation were in the ranges of 2.13 %-3.59 % and 2.30 %-3.35 %, respectively. In the training set, we identified that at a PymiR Score of 71.78, the maximum sensitivity and specificity for the detection of BKVAN were 76.9 % and 100 % respectively, with the receiver-operator characteristic (ROC) analysis showing an area under the curve of 0.8681. In the validation set, we observed a significant difference in the PymiR Score between BKV infection and biopsy-proven BKVAN (P < 0.05), with the ROC analysis showing a sensitivity of 72.73 %, specificity of 100 %, and an AUC of 0.8571. Compared with the area under the ROC curve of plasma BK virus DNA load (AUC = 0.7266), the PymiR Score exhibited higher discrimination capacity (P<0.05) between BKV infection and biopsy-proven BKVAN. Overall, this non-invasive approach offers a robust and convenient alternative for the diagnosis of BK polyomavirus-associated nephropathy.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120162"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120162","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Noninvasive detection of BK virus, for early detection of BK polyomavirus-associated nephropathy post-renal transplantation, is currently an active subject of investigation. In this study, we developed and validated a novel risk score diagnostic assay (PymiR Score) based on measurements of three urine miRNAs, including BKV-related miRNA (bkv-miR-B1-5p), polyomavirus-related miRNA (bkv-miR-B1-3p) and renal tubular injury-related miRNA (miR-21-5p), by quantitative polymerase chain reaction. The limit of detection of the three miRNAs was 2 × 103 copies/mL, while the intra- and inter-assay coefficients of variation were in the ranges of 2.13 %-3.59 % and 2.30 %-3.35 %, respectively. In the training set, we identified that at a PymiR Score of 71.78, the maximum sensitivity and specificity for the detection of BKVAN were 76.9 % and 100 % respectively, with the receiver-operator characteristic (ROC) analysis showing an area under the curve of 0.8681. In the validation set, we observed a significant difference in the PymiR Score between BKV infection and biopsy-proven BKVAN (P < 0.05), with the ROC analysis showing a sensitivity of 72.73 %, specificity of 100 %, and an AUC of 0.8571. Compared with the area under the ROC curve of plasma BK virus DNA load (AUC = 0.7266), the PymiR Score exhibited higher discrimination capacity (P<0.05) between BKV infection and biopsy-proven BKVAN. Overall, this non-invasive approach offers a robust and convenient alternative for the diagnosis of BK polyomavirus-associated nephropathy.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.